Regeneron Reports Results of Eylea (aflibercept) in P-III PANORAMA Study for Patients with Diabetic Retinopathy

 Regeneron Reports Results of Eylea (aflibercept) in P-III PANORAMA Study for Patients with Diabetic Retinopathy

Regeneron Reports Results of Eylea (aflibercept) in P-III PANORAMA Study for Patients with Diabetic Retinopathy

Shots:

  • The P-III PANORAMA study involves assessing Eylea [inj. 2mg (0.05ml), q8w/q16w] vs sham in 402 patients with moderately severe to severe NPDR without DME
  • The P-III PANORAMA study results: @2yrs. 75% reduction in vision-threatening events, patients demonstrated greater improvement in the DRSS score from baseline (80% @52wks and 50% @100 wks.) in q8w group while >2-step DRSS scores remained consistent (65% @52 wks. vs 62% @100 wks.) in q16w group
  • Eylea is a VEGF inhibitor targeting VEGF-A and PLGF, formulated as an injection for the eye, act by blocking the growth of new blood vessels and by decreasing vascular permeability in the eye and is approved therapy for Wet AMD, macular edema following RVO, DME and DR in the US 

Click here ­to­ read full press release/ article | Ref: Regeneron | Image: StraitTimes

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post